Literature DB >> 9200394

Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model.

C M O'Connor1, W R Hathaway, E R Bates, J D Leimberger, K N Sigmon, D J Kereiakes, B S George, J K Samaha, C W Abbottsmith, R J Candela, E J Topol, R M Califf.   

Abstract

Ischemic heart disease is the most common cause of congestive heart failure, which often begins after acute myocardial infarction. To better delineate the clinical characteristics and outcomes of patients in whom congestive heart failure develops after acute myocardial infarction in the thrombolytic era, we prospectively evaluated patients enrolled in six of the TAMI trials. The study cohort comprised 1619 consecutive patients who had at least 1 mm of ST-segment elevation in two contiguous electrocardiographic leads within 6 hours of the onset of acute myocardial infarction and who received intravenous thrombolytic therapy. We prospectively collected clinical characteristics, baseline demographics, acute and 1-week angiographic variables, and in-hospital and 1-year outcome data. We performed stepwise multivariable regression analysis to determine the noninvasive and invasive predictors of the development of in-hospital congestive heart failure. Congestive heart failure developed in 301 patients in the hospital (19% of 1521 patients admitted were not in heart failure). These patients were likely to be older and female, have diabetes mellitus and previous myocardial infarction, and have an anterior wall myocardial infarction. On acute angiography, they had lower ejection fractions and a higher incidence of multivessel disease. Patency at 90 minutes was lower in the patients with congestive heart failure, and acute mitral regurgitation occurred in 1.6% versus 0.21% of patients without congestive heart failure. Patients with congestive heart failure had higher mortality, more in-hospital complications, and longer hospitalizations. At 1-year follow up, 21% of the patients in whom congestive heart failure developed had died versus 5% in the group without congestive heart failure. Predictors of new congestive heart failure included increased age, anterior wall myocardial infarction, lower pulse pressure and systolic blood pressure, diabetes mellitus, and the presence of rales on admission. The acute angiographic variables of reduced ejection fraction, increased number of diseased vessels, and attempted percutaneous intervention improved the concordance of the predictive model by 6%. Congestive heart failure remains a common clinical problem after acute myocardial infarction and is associated with a twofold increase in in-hospital morbidity and a fourfold increase in in-hospital and 1-year mortality. The development of congestive heart failure in the hospital can be predicted from noninvasive and invasive baseline characteristics. We present a simple table to predict congestive heart failure from baseline characteristics and invasive information.

Entities:  

Mesh:

Year:  1997        PMID: 9200394     DOI: 10.1016/s0002-8703(97)70168-6

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  17 in total

1.  Long-term alcohol consumption in relation to all-cause and cardiovascular mortality among survivors of myocardial infarction: the Health Professionals Follow-up Study.

Authors:  Jennifer K Pai; Kenneth J Mukamal; Eric B Rimm
Journal:  Eur Heart J       Date:  2012-03-27       Impact factor: 29.983

2.  Atherosclerotic Burden and Heart Failure After Myocardial Infarction.

Authors:  Yariv Gerber; Susan A Weston; Maurice Enriquez-Sarano; Sheila M Manemann; Alanna M Chamberlain; Ruoxiang Jiang; Véronique L Roger
Journal:  JAMA Cardiol       Date:  2016-05-01       Impact factor: 14.676

3.  Percutaneous left ventricular partitioning device for chronic heart failure.

Authors:  K Boerlage-van Dijk; P G Meregalli; R N Planken; K T Koch; J Baan
Journal:  Neth Heart J       Date:  2012-12       Impact factor: 2.380

4.  Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction: the HF-ACTION predictive risk score model.

Authors:  Christopher M O'Connor; David J Whellan; Daniel Wojdyla; Eric Leifer; Robert M Clare; Stephen J Ellis; Lawrence J Fine; Jerome L Fleg; Faiez Zannad; Steven J Keteyian; Dalane W Kitzman; William E Kraus; David Rendall; Ileana L Piña; Lawton S Cooper; Mona Fiuzat; Kerry L Lee
Journal:  Circ Heart Fail       Date:  2011-11-23       Impact factor: 8.790

Review 5.  Therapies to prevent heart failure post-myocardial infarction.

Authors:  Kevin L Thomas; Eric J Velazquez
Journal:  Curr Heart Fail Rep       Date:  2005-12

6.  Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score.

Authors:  Christopher M O'Connor; Vic Hasselblad; Rajendra H Mehta; Gudaye Tasissa; Robert M Califf; Mona Fiuzat; Joseph G Rogers; Carl V Leier; Lynne W Stevenson
Journal:  J Am Coll Cardiol       Date:  2010-03-02       Impact factor: 24.094

Review 7.  Adult Bone Marrow Cell Therapy for Ischemic Heart Disease: Evidence and Insights From Randomized Controlled Trials.

Authors:  Muhammad R Afzal; Anweshan Samanta; Zubair I Shah; Vinodh Jeevanantham; Ahmed Abdel-Latif; Ewa K Zuba-Surma; Buddhadeb Dawn
Journal:  Circ Res       Date:  2015-07-09       Impact factor: 17.367

Review 8.  Diabetes and heart failure in the post-myocardial infarction patient.

Authors:  Jerry D Estep; David Aguilar
Journal:  Curr Heart Fail Rep       Date:  2006-12

Review 9.  Glucose and insulin management in the post-MI setting.

Authors:  Patrick H McNulty
Journal:  Curr Diab Rep       Date:  2002-02       Impact factor: 4.810

10.  ECG quantification of myocardial scar and risk stratification in MADIT-II.

Authors:  Zak Loring; Wojciech Zareba; Scott McNitt; David G Strauss; Galen S Wagner; James P Daubert
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-06-09       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.